Product information and disease descriptionProduct descriptionProduct information
Access and distribution
6 evidence topics · 6 sources
Expanded access: intermediate-size cohort program for tumor HI
Expanded access: company program and eligibility
Expanded access: physician request and drug supplied at no cost
“Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated care setting at launch: National Cancer Institutes and academic medical centers
Anticipated reimbursement: prior authorization and J-code buy and bill
Distribution rights in the Republic of Korea
Specialty pharmacy or distribution network
No evidence found.